FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to medicine and relates to a pharmaceutical composition for the treatment of autoimmune diseases of a human comprising adalimumab and a structural stabilizer selected from sucrose and trehalose. Said pharmaceutical composition does not contain sodium chloride. Group of inventions also relates to the use of said pharmaceutical composition for the preparation of a medicament for the treatment of autoimmune diseases in humans.
EFFECT: group of inventions provides high stability of the adalimumab composition.
13 cl, 1 dwg, 10 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| LIQUID COMPOSITION OF AN ANTIBODY AGAINST TNF ALPHA | 2018 |
|
RU2756619C2 |
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING BIOPHARMACEUTICAL DRUG | 2011 |
|
RU2587056C2 |
| PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF | 2018 |
|
RU2749342C1 |
| ALTERNATIVE COMPOSITIONS FOR TNFR:FC CHIMERICAL POLYPEPTIDES | 2014 |
|
RU2663727C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND USE THEREOF | 2021 |
|
RU2791857C2 |
